U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Lung Non-Small Cell Squamous Carcinoma

MedGen UID:
1750219
•Concept ID:
C5419073
•
Neoplastic Process

Definition

The reemergence of lung squamous non-small cell carcinoma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Lung Non-Small Cell Squamous Carcinoma

Professional guidelines

PubMed

A potential treatment option for advanced non-small cell lung cancer: Three cases.
Lee S, Park S, Lee HY, Jeon H, Lee S, Choi S, Eo W
Explore (NY) 2023 May-Jun;19(3):453-457. Epub 2022 Apr 5 doi: 10.1016/j.explore.2022.04.001. PMID: 35431108
Pemetrexed in the treatment of advanced non-squamous lung cancer.
Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C
Lung Cancer 2009 Nov;66(2):141-9. Epub 2009 Jul 4 doi: 10.1016/j.lungcan.2009.06.006. PMID: 19577816
Systemic treatment of advanced non-small cell lung cancer.
Traynor AM, Schiller JH
Drugs Today (Barc) 2004 Aug;40(8):697-710. doi: 10.1358/dot.2004.40.8.850472. PMID: 15510241

Recent clinical studies

Etiology

Extracellular matrix profiles determine risk and prognosis of the squamous cell carcinoma subtype of non-small cell lung carcinoma.
Parker AL, Bowman E, Zingone A, Ryan BM, Cooper WA, Kohonen-Corish M, Harris CC, Cox TR
Genome Med 2022 Nov 21;14(1):126. doi: 10.1186/s13073-022-01127-6. PMID: 36404344Free PMC Article
Immunonutritional Indices in Non-small-cell Lung Cancer Patients Receiving Adjuvant Platinum-based Chemotherapy.
Matsubara T, Hirai F, Yamaguchi M, Hamatake M
Anticancer Res 2021 Oct;41(10):5157-5163. doi: 10.21873/anticanres.15333. PMID: 34593467
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA
Clin Lung Cancer 2021 May;22(3):170-177. Epub 2020 Oct 14 doi: 10.1016/j.cllc.2020.09.013. PMID: 33221175Free PMC Article
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS
Lancet Oncol 2020 Dec;21(12):1589-1601. Epub 2020 Oct 27 doi: 10.1016/S1470-2045(20)30475-7. PMID: 33125909Free PMC Article
miRNA and cancer; computational and experimental approaches.
Tutar Y
Curr Pharm Biotechnol 2014;15(5):429. doi: 10.2174/138920101505140828161335. PMID: 25189575

Diagnosis

Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, Okamoto T, Akamatsu H, Oki M, Sato Y, Tobino K, Ikeda S, Mori M, Mimura C, Maeno K, Miura S, Harada T, Nishimura K, Hiraoka M, Kenmotsu H, Fujimoto J, Shimokawa M, Yamamoto N, Nakagawa K
JAMA Netw Open 2023 Dec 1;6(12):e2347700. doi: 10.1001/jamanetworkopen.2023.47700. PMID: 38100106Free PMC Article
Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients.
Foy JP, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J, Fekiri D, Robert M, Baffert KA, Hervé G, Quilhot P, Attignon V, Girod A, Chaine A, Benassarou M, Zrounba P, Caux C, Ghiringhelli F, Lantuejoul S, Crozes C, Brochériou I, Pérol M, Fayette J, Bertolus C, Saintigny P
Eur J Cancer 2022 Oct;174:287-298. Epub 2022 Aug 26 doi: 10.1016/j.ejca.2022.06.034. PMID: 36038492
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Yoo SY, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Bassukas ID, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG
Lancet Oncol 2021 Jun;22(6):848-857. Epub 2021 May 14 doi: 10.1016/S1470-2045(21)00126-1. PMID: 34000246
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS
Lancet Oncol 2020 Dec;21(12):1589-1601. Epub 2020 Oct 27 doi: 10.1016/S1470-2045(20)30475-7. PMID: 33125909Free PMC Article
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer.
Grunnet M, Sorensen JB
Lung Cancer 2012 May;76(2):138-43. Epub 2011 Dec 6 doi: 10.1016/j.lungcan.2011.11.012. PMID: 22153832

Therapy

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Bordenave S, Juan-Vidal O, Menezes J, Reinmuth N, Richardet E, Cheng Y, Mizutani H, Felip E, Zurawski B, Alexandru A, Paz-Ares L, Lu S, John T, Zhang X, Mahmood J, Hu N, De T, Santi I, Penrod JR, Yuan Y, Lee A, Reck M
J Immunother Cancer 2024 Feb 12;12(2) doi: 10.1136/jitc-2023-008189. PMID: 38346853Free PMC Article
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.
Tewari KS, Colombo N, Monk BJ, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüs M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Toker S, Keefe SM, Lorusso D
JAMA Oncol 2024 Feb 1;10(2):185-192. doi: 10.1001/jamaoncol.2023.5410. PMID: 38095881Free PMC Article
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS
Lancet Oncol 2020 Dec;21(12):1589-1601. Epub 2020 Oct 27 doi: 10.1016/S1470-2045(20)30475-7. PMID: 33125909Free PMC Article
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE
Lancet Oncol 2016 Jul;17(7):984-993. Epub 2016 Jun 6 doi: 10.1016/S1470-2045(16)30146-2. PMID: 27283860Free PMC Article
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH
N Engl J Med 2006 Dec 14;355(24):2542-50. doi: 10.1056/NEJMoa061884. PMID: 17167137

Prognosis

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.
Borghaei H, O'Byrne KJ, Paz-Ares L, Ciuleanu TE, Yu X, Pluzanski A, Nagrial A, Havel L, Kowalyszyn RD, Valette CA, Brahmer JR, Reck M, Ramalingam SS, Zhang L, Ntambwe I, Rabindran SK, Nathan FE, Balli D, Wu YL
ESMO Open 2023 Dec;8(6):102065. Epub 2023 Nov 20 doi: 10.1016/j.esmoop.2023.102065. PMID: 37988950Free PMC Article
Extracellular matrix profiles determine risk and prognosis of the squamous cell carcinoma subtype of non-small cell lung carcinoma.
Parker AL, Bowman E, Zingone A, Ryan BM, Cooper WA, Kohonen-Corish M, Harris CC, Cox TR
Genome Med 2022 Nov 21;14(1):126. doi: 10.1186/s13073-022-01127-6. PMID: 36404344Free PMC Article
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA
Clin Lung Cancer 2021 May;22(3):170-177. Epub 2020 Oct 14 doi: 10.1016/j.cllc.2020.09.013. PMID: 33221175Free PMC Article
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ
Lancet Oncol 2017 Jan;18(1):31-41. Epub 2016 Dec 5 doi: 10.1016/S1470-2045(16)30624-6. PMID: 27932067Free PMC Article
LRIG and cancer prognosis.
Lindquist D, Kvarnbrink S, Henriksson R, Hedman H
Acta Oncol 2014 Sep;53(9):1135-42. Epub 2014 Sep 2 doi: 10.3109/0284186X.2014.953258. PMID: 25180912Free PMC Article

Clinical prediction guides

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Bordenave S, Juan-Vidal O, Menezes J, Reinmuth N, Richardet E, Cheng Y, Mizutani H, Felip E, Zurawski B, Alexandru A, Paz-Ares L, Lu S, John T, Zhang X, Mahmood J, Hu N, De T, Santi I, Penrod JR, Yuan Y, Lee A, Reck M
J Immunother Cancer 2024 Feb 12;12(2) doi: 10.1136/jitc-2023-008189. PMID: 38346853Free PMC Article
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.
Tewari KS, Colombo N, Monk BJ, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüs M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Toker S, Keefe SM, Lorusso D
JAMA Oncol 2024 Feb 1;10(2):185-192. doi: 10.1001/jamaoncol.2023.5410. PMID: 38095881Free PMC Article
Extracellular matrix profiles determine risk and prognosis of the squamous cell carcinoma subtype of non-small cell lung carcinoma.
Parker AL, Bowman E, Zingone A, Ryan BM, Cooper WA, Kohonen-Corish M, Harris CC, Cox TR
Genome Med 2022 Nov 21;14(1):126. doi: 10.1186/s13073-022-01127-6. PMID: 36404344Free PMC Article
Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
Scribner JA, Brown JG, Son T, Chiechi M, Li P, Sharma S, Li H, De Costa A, Li Y, Chen Y, Easton A, Yee-Toy NC, Chen FZ, Gorlatov S, Barat B, Huang L, Wolff CR, Hooley J, Hotaling TE, Gaynutdinov T, Ciccarone V, Tamura J, Koenig S, Moore PA, Bonvini E, Loo D
Mol Cancer Ther 2020 Nov;19(11):2235-2244. Epub 2020 Sep 23 doi: 10.1158/1535-7163.MCT-20-0116. PMID: 32967924
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer.
Grunnet M, Sorensen JB
Lung Cancer 2012 May;76(2):138-43. Epub 2011 Dec 6 doi: 10.1016/j.lungcan.2011.11.012. PMID: 22153832

Recent systematic reviews

Impact of bone metastasis on the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Liu L, Shi Z, Qiu X
Clin Transl Oncol 2024 Mar;26(3):747-755. Epub 2023 Aug 11 doi: 10.1007/s12094-023-03300-8. PMID: 37566344
Predictive Role of Tumor-Stroma Ratio for Survival of Patients With Non-Small Cell Lung Cancer: A Meta-Analysis.
Zhang X, Ma H, Zhang L, Li F
Pathol Oncol Res 2021;27:1610021. Epub 2022 Jan 21 doi: 10.3389/pore.2021.1610021. PMID: 35132307Free PMC Article
Tumor Spread Through Air Spaces in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Chen D, Mao Y, Wen J, She Y, Zhu E, Zhu F, Zhang Y, Fan M, Chen C, Chen Y
Ann Thorac Surg 2019 Sep;108(3):945-954. Epub 2019 Mar 23 doi: 10.1016/j.athoracsur.2019.02.045. PMID: 30914285
Change of Circulating and Tissue-Based miR-20a in Human Cancers and Associated Prognostic Implication: A Systematic Review and Meta-Analysis.
Zhang Q, Wang Q, Sun W, Gao F, Liu L, Cheng L, Li Z
Biomed Res Int 2018;2018:6124927. Epub 2018 Nov 25 doi: 10.1155/2018/6124927. PMID: 30596096Free PMC Article
Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies.
Tang H, Wang S, Xiao G, Schiller J, Papadimitrakopoulou V, Minna J, Wistuba II, Xie Y
Ann Oncol 2017 Apr 1;28(4):733-740. doi: 10.1093/annonc/mdw683. PMID: 28200038Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...